600056.SHG China Meheco Co Ltd
- Market cap
- CNY 13.5B
- P/E
- 43.0x
- P/B
- 1.12x
- ROE
- 3.2%
- Dividend yield
- 2.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600056.SHG undervalued?
Graham number600056.SHG trades 46.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China Meheco Co Ltd fundamental analysis
No fundamental analysis for China Meheco Co Ltd yet.
China Meheco Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China Meheco Co Ltd
China Meheco Group Co., Ltd. operates in pharmaceutical industry in China and internationally. The company is involved in international trade of pharmaceuticals, including pharmaceutical preparations, drug substances, intermediates, medical devices, medical consumables, Chinese medicinal materials, and extracts; and pharmaceutical commerce business. It also provides supply chain services, such as sales agency, logistics and distribution, warehousing, equipment bidding, repai…
Full company profileChina Meheco Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
China Meheco Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 25.9B | 30.4B | 31.0B | 35.3B | 39.3B | 36.2B | 37.6B | 38.8B | 34.1B | 35.4B | 33.3B |
| Gross Profit | 3.07B | 4.37B | 6.41B | 6.36B | 6.36B | 4.69B | 4.64B | 4.35B | 3.60B | 3.71B | 3.47B |
| Operating Income | 1.42B | 2.06B | 2.29B | 1.69B | 1.94B | 937M | 1.20B | 1.67B | 932M | 1.41B | 1.20B |
| EBITDA | 1.61B | 2.12B | 2.09B | 2.08B | 2.86B | 1.59B | 1.69B | 1.59B | 1.51B | 1.70B | 971M |
| Net Income | 950M | 1.31B | 1.54B | 981M | 1.31B | 647M | 736M | 1.05B | 535M | 473M | 388M |
| EPS | 0.66 | 1.23 | 1.03 | 0.92 | 1.23 | 0.43 | 0.49 | 0.70 | 0.36 | 0.32 | 0.26 |
| Balance Sheet | |||||||||||
| Total Assets | 19.5B | 21.2B | 25.3B | 29.8B | 33.2B | 31.1B | 35.9B | 37.4B | 35.3B | 36.9B | 38.7B |
| Total Liabilities | 11.8B | 12.3B | 15.2B | 18.8B | 21.0B | 18.6B | 22.7B | 23.5B | 21.2B | 22.5B | 24.1B |
| Shareholders' Equity | 6.88B | 7.76B | 8.45B | 8.99B | 10.0B | 10.3B | 10.8B | 11.6B | 11.8B | 11.8B | 12.0B |
| Cash & Short-term Investments | 3.09B | 3.34B | 3.73B | 2.83B | 3.57B | 2.80B | 4.26B | 3.87B | 4.34B | 4.09B | 3.34B |
| Total Debt | 669M | 670M | 1.37B | 3.98B | 4.49B | 4.69B | 5.38B | 5.02B | 5.75B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.00B | 509M | 258K | -53.8M | 1.56B | 148M | 1.65B | 859M | 1.01B | 1.43B | - |
| Capital Expenditure | 154M | 109M | 262M | 280M | 318M | 286M | 229M | 363M | 359M | 333M | 241M |
| Free Cash Flow | 850M | 401M | -262M | -334M | 1.24B | -138M | 1.42B | 497M | 647M | 1.09B | -1.04B |
| Ratios | |||||||||||
| ROE | 13.8% | 16.9% | 18.3% | 10.9% | 13.1% | 6.3% | 6.8% | 9.1% | 4.5% | 4.0% | 3.2% |
| ROA | 4.9% | 6.2% | 6.1% | 3.3% | 3.9% | 2.1% | 2.0% | 2.8% | 1.5% | 1.3% | 1.0% |
| Net Profit Margin | 3.7% | 4.3% | 5.0% | 2.8% | 3.3% | 1.8% | 2.0% | 2.7% | 1.6% | 1.3% | 1.2% |
| Debt to Equity | 0.10x | 0.09x | 0.16x | 0.44x | 0.45x | 0.46x | 0.50x | 0.43x | 0.49x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
China Meheco Co Ltd dividends
- Dividend yield
- 2.25%
- Forward dividend
- 0.09 CNY
- Payout ratio
- 64.1%
- Ex-dividend date
- Jun 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 304M | 0.20 | 64.1% |
| 2024 | CNY 511M | 0.34 | 95.4% |
| 2023 | CNY 368M | 0.25 | 35.1% |
| 2022 | CNY 622M | 0.42 | 84.5% |
| 2021 | CNY 393M | 0.26 | 60.8% |
| 2020 | CNY 294M | 0.28 | 22.5% |
| 2019 | CNY 463M | 0.43 | 47.2% |
| 2018 | CNY 446M | 0.30 | 28.9% |
| 2017 | CNY 315M | 0.30 | 24.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 24, 2022.
Who owns China Meheco Co Ltd
- Insiders 53.59%
- Institutions 0.53%
- Public & others 45.88%
- Shares outstanding 1.50B
- Free float 707M
China Meheco Co Ltd company profile
- Company name
- China Meheco Co Ltd
- Ticker
- 600056.SHG
- ISIN
- CNE000000Q29
- Exchange
- Shanghai Stock Exchange
- Listed since
- Apr 28, 1997
- Sector
- Healthcare
- Industry
- Trading Companies & Distributors
- Employees
- 7,949
- Fiscal year end
- December
- Address
- Apartment B, General Times Center, Building 1, Beijing, China, 100061
- Phone
- 86 10 8116 7788
- Website
- meheco.com
About China Meheco Co Ltd
China Meheco Group Co., Ltd. operates in pharmaceutical industry in China and internationally. The company is involved in international trade of pharmaceuticals, including pharmaceutical preparations, drug substances, intermediates, medical devices, medical consumables, Chinese medicinal materials, and extracts; and pharmaceutical commerce business. It also provides supply chain services, such as sales agency, logistics and distribution, warehousing, equipment bidding, repair and maintenance, clinical value promotion, department planning, design, co-construction, operation and maintenance, SPD, and other services for various areas comprising vascular interventional therapy, non-interventional therapy, orthopedic implantation, neurosurgery, electrophysiology, pacemakers, extracorporeal circulation and blood purification, ophthalmology, and stomatology. Its drug products cover therapeutic fields, such as anti-infection, cardiovascular and cerebrovascular, hormones and endocrine regulation, respiratory and digestive systems, nutritional supplements, antipyretic and analgesics, and other therapeutic areas, as well as Chinese herbal materials and prepared slices. The company was founded in 1983 and is based in Beijing, China.
China Meheco Co Ltd management
8- Mr. Guang YangChairman & GM · born 1975
- Ms. Xiaohong GeChief Accountant · born 1977
- Mr. Jian ZhangGeneral Counsel · born 1977
- Mr. Jing Hua YuanBoard Secretary · born 1978
- Mr. Huibo ZhangAssistant to General Manager · born 1983
- Mr. Peng ZhangDeputy General Manager · born 1977
- Ms. Lin ZhangBoard Secretary · born 1986
- Mr. Peng ZhangDeputy General Manager · born 1977